In one study, METTL3 promoted the expression of MDR1 and ABCG2 (commonly known as breast cancer‐resistant protein, BCRP) through m6A modification and maturation of miR‐221‐3p.[58] In chemoresistant breast and liver cancer, increased expression of METTL3 indirectly causes resistance of cancerous cells to doxorubicin and taxol. This evidence concerns the gene METTL3 and liver cancer.